| Product NDC: | 0179-0030 |
| Proprietary Name: | BuPROPion Hydrochloride |
| Non Proprietary Name: | BuPROPion Hydrochloride |
| Active Ingredient(s): | 150 mg/1 & nbsp; BuPROPion Hydrochloride |
| Administration Route(s): | ORAL |
| Dosage Form(s): | TABLET, EXTENDED RELEASE |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 0179-0030 |
| Labeler Name: | KAISER FOUNDATION HOSPITALS |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | ANDA079095 |
| Marketing Category: | ANDA |
| Start Marketing Date: | 20090831 |
| Package NDC: | 0179-0030-70 |
| Package Description: | 30 TABLET, EXTENDED RELEASE in 1 BOX, UNIT-DOSE (0179-0030-70) |
| NDC Code | 0179-0030-70 |
| Proprietary Name | BuPROPion Hydrochloride |
| Package Description | 30 TABLET, EXTENDED RELEASE in 1 BOX, UNIT-DOSE (0179-0030-70) |
| Product NDC | 0179-0030 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | BuPROPion Hydrochloride |
| Dosage Form Name | TABLET, EXTENDED RELEASE |
| Route Name | ORAL |
| Start Marketing Date | 20090831 |
| Marketing Category Name | ANDA |
| Labeler Name | KAISER FOUNDATION HOSPITALS |
| Substance Name | BUPROPION HYDROCHLORIDE |
| Strength Number | 150 |
| Strength Unit | mg/1 |
| Pharmaceutical Classes | Aminoketone [EPC],Dopamine Uptake Inhibitors [MoA],Increased Dopamine Activity [PE],Increased Norepinephrine Activity [PE],Norepinephrine Uptake Inhibitors [MoA] |